(Reuters)—Malaria drug hydroxychloroquine (HCQ), which U.S. President Donald Trump says he has been taking, is tied to increased risk of death in COVID-19 patients, according to a study published in The Lancet.1 The registry analysis, which included data from 671 hospitals in six continents and over 96,000 patients hospitalized with COVID-19, showed that people treated…
U.K. Healthcare Workers Begin COVID-19 HCQ Trial
LONDON (Reuters)—On May 21, British healthcare workers began taking part in a University of Oxford-led international trial of two anti-malarial drugs to see if they can prevent COVID-19, including one U.S. President Donald Trump says he has been taking. The COPCOV study will involve more than 40,000 frontline healthcare workers from Europe, Africa, Asia and…
Rheumatology Biologic Expertise Valued for COVID-19 Treatment Decisions
At the Loma Linda University Medical Center, Calif., rheumatologists play a key consulting role for COVID-19 patients who may benefit from the use of biologic treatments…
Tips for Understanding the Pathways of Pain & Choosing Treatments
SNOWMASS VILLAGE, COLO.—The science underlying the neurobiology of chronic pain isn’t something rheumatologists often think about. However, pain is an important reason why patients see a rheumatologist. At the 2020 ACR Winter Symposium in January, Leslie Crofford, MD, gave two presentations addressing pain experienced by rheumatology patients, including a session on the fundamental mechanisms of…
Rheumatoid Arthritis Therapy Update: What’s Changed & What’s the Same
SNOWMASS VILLAGE, COLO.—Current trends in rheumatoid arthritis (RA) therapy are the increased use of newer medication categories, such as Janus kinase (JAK) inhibitors (Jakinibs) and biologics, and the rising costs of treatment. Unchanged is the consistent use of methotrexate as an effective therapy. These topics and more were discussed at the ACR Winter Symposium during…
Studies Suggest Similar Risks for Biologics vs. Conventional Therapies for Rheumatoid Arthritis
Two new studies delving into the relative safety of biologic drugs prescribed for rheumatoid arthritis (RA) have concluded that real-world applications of abatacept and tumor necrosis factor inhibitors (TNFi’s) are comparable to more conventional therapies in their associated risk of serious infections. Triple Therapy One study, in Arthritis Care & Research, found the risk of…
Hydroxychloroquine for COVID-19 Fails Another Test
(Reuters)—The malaria treatment repeatedly championed by U.S. President Donald Trump as a game changer in the fight against the novel coronavirus has again failed to show a benefit in patients hospitalized with COVID-19, according to a recent study. Although the study published in The New England Journal of Medicine had certain limitations, doctors report that…
Arthritis Drug Anakinra Shows Promise in COVID-19
NEW YORK (Reuters Health)—Treatment with the interleukin-1 blocker anakinra appears to improve respiratory symptoms and reduced signs of cytokine storm in nearly three-quarters of patients with acute respiratory distress and cytokine release syndrome from COVID-19 in a small retrospective study from Italy. “Our study is the first to suggest that a high dose of the…
Baricitinib Studied as Possible COVID-19 Treatment; Plus Ranitidine Removed from U.S. Market
Baricitinib, an oral JAK1/JAK2 inhibitor approved to treat RA in adults, is being investigated as a possible treatment for hospitalized patients with COVID-19…
HCQ Prolongs QT Interval in Patients with COVID-19
NEW YORK (Reuters Health)—Potentially dangerous prolongation of the QT interval is common among patients hospitalized with COVID-19 who receive hydroxychloroquine (HCQ) with or without concomitant azithromycin, according to two new studies. “This is a well-known problem with HCQ and azithromycin, which became amplified in this higher risk population,” Christina F. Yen, MD, from Beth Israel…
- « Previous Page
- 1
- …
- 27
- 28
- 29
- 30
- 31
- …
- 123
- Next Page »